NYSE:NVRONevro Stock Price, Forecast & News

Nevro's stock was trading at $109.82 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NVRO stock has increased by 14.4% and is now trading at $125.60. View which stocks have been most impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 1 sell rating, 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Nevro.

Nevro is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Nevro.

Nevro Corp (NYSE:NVRO) released its earnings results on Tuesday, May, 5th. The medical equipment provider reported ($0.78) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.99) by $0.21. The medical equipment provider earned $87.47 million during the quarter, compared to the consensus estimate of $86.70 million. Nevro had a negative net margin of 21.36% and a negative return on equity of 40.67%. The company's revenue was up 6.5% compared to the same quarter last year. During the same period last year, the company earned ($1.45) earnings per share. View Nevro's earnings history.

Nevro updated its first quarter 2020 After-Hours earnings guidance on Wednesday, April, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $86.4-86.9 million, compared to the consensus revenue estimate of $96.96 million.

12 equities research analysts have issued 12 month target prices for Nevro's shares. Their forecasts range from $65.00 to $158.00. On average, they anticipate Nevro's stock price to reach $115.33 in the next twelve months. This suggests that the stock has a possible downside of 8.2%. View analysts' price targets for Nevro.

News coverage about NVRO stock has been trending very negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Nevro earned a daily sentiment score of -3.4 on InfoTrie's scale. They also assigned press coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutNevro.

Some companies that are related to Nevro include Teleflex (TFX), Insulet (PODD), ABIOMED (ABMD), Novocure (NVCR), Hill-Rom (HRC), Penumbra (PEN), Haemonetics (HAE), Globus Medical (GMED), Tandem Diabetes Care (TNDM), Integra Lifesciences (IART), ICU Medical (ICUI), Irhythm Technologies (IRTC), NuVasive (NUVA), Merit Medical Systems (MMSI) and Inovio Pharmaceuticals (INO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), Adobe (ADBE), AbbVie (ABBV), Trade Desk (TTD), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Shopify (SHOP) and Vertex Pharmaceuticals (VRTX).

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Nevro's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.29%), Fred Alger Management LLC (5.83%), Invesco Ltd. (4.17%), Franklin Resources Inc. (3.64%), Perceptive Advisors LLC (3.21%) and Lord Abbett & CO. LLC (2.28%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Elizabeth H Weatherman, Kevin C Oboyle and Shawn Mccormick. View institutional ownership trends for Nevro.

NVRO stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Balyasny Asset Management LLC, ArrowMark Colorado Holdings LLC, Franklin Resources Inc., Federated Hermes Inc., Nuveen Asset Management LLC, Engineers Gate Manager LP, and Invesco Ltd.. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan, Doug Alleavitch, and Shawn Mccormick. View insider buying and selling activity for Nevro.

NVRO stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, BlackRock Inc., Lord Abbett & CO. LLC, Two Sigma Advisers LP, Castleark Management LLC, Fred Alger Management LLC, Rock Springs Capital Management LP, and Deutsche Bank AG. Company insiders that have bought Nevro stock in the last two years include Elizabeth H Weatherman, and Kevin C Oboyle. View insider buying and selling activity for Nevro.

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVRO stock can currently be purchased for approximately $125.60.

Nevro has a market capitalization of $4.27 billion and generates $390.26 million in revenue each year. The medical equipment provider earns $-103,690,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Nevro employs 804 workers across the globe.

The official website for Nevro is www.nevro.com.

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]